Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H2 2018 –

PUNE, India, September 05, 2018 /ResearchByMarkets/—  Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H2 2018, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 34, 29, 7, 106 and 37 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.



– The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Companies Mentioned 
Abide Therapeutics Inc
AdAlta Ltd
Akcea Therapeutics Inc
Albireo Pharma Inc
Aldeyra Therapeutics Inc
Allergan Plc
Araim Pharmaceuticals Inc
Arcturus Therapeutics Ltd
Ardelyx Inc
Ascletis Inc
Assembly Biosciences Inc
AstraZeneca Plc
Baliopharm AG
Betagenon AB
BioElectron Technology Corp
Bird Rock Bio Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Can-Fite BioPharma Ltd
Cardax Inc
Carmot Therapeutics Inc
Catabasis Pharmaceuticals Inc
Celgene Corp
Cerenis Therapeutics Holding SA
ChemoCentryx Inc
CJ HealthCare Corp
CohBar Inc
ConSynance Therapeutics Inc
CymaBay Therapeutics Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Dicerna Pharmaceuticals Inc
Dimerix Bioscience Pty Ltd
Dong-A Socio Holdings Co Ltd
Eli Lilly and Co
Enanta Pharmaceuticals Inc
Enyo Pharma SA
Esperion Therapeutics Inc
Exicure Inc
Forma Therapeutics Inc
Galectin Therapeutics Inc
Galecto Biotech AB
Galmed Pharmaceuticals Ltd
Gemphire Therapeutics Inc
Genfit SA
GenKyoTex SA
Gilead Sciences Inc
GRI Bio Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
HemoShear Therapeutics, LLC
IB Pharmaceuticals Inc
iCo Therapeutics Inc
Immupharma Plc
Immuron Ltd
Integral Molecular Inc
Intercept Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Kowa Co Ltd
Kyorin Pharmaceutical Co Ltd
Madrigal Pharmaceuticals Inc
MallInckrodt Plc
MedImmune LLC
Merck & Co Inc
Metabolys SAS
Metacrine Inc
Mina Therapeutics Ltd
Mitsubishi Tanabe Pharma Corp
Naia Ltd
NeuroVive Pharmaceutical AB
NGM Biopharmaceuticals Inc
Nippon Chemiphar Co Ltd
NorthSea Therapeutics BV
Novartis AG
NovaTarg Therapeutics Inc
Novo Nordisk AS
Nuevolution AB
NuSirt Biopharma Inc
Oramed Pharmaceuticals Inc
Pfizer Inc
Pharmaxis Ltd
Poxel SA
Promethera Biosciences SA
ProMetic Life Sciences Inc
Protalix BioTherapeutics Inc
Redx Pharma Plc
Regulus Therapeutics Inc
Ritter Pharmaceuticals Inc
Saje Pharma LLC
Sancilio & Company Inc
ScandiCure AB
Second Genome Inc
Seres Therapeutics Inc
Shire Plc
Sprint Bioscience AB
Synlogic Inc
TaiwanJ Pharmaceuticals Co Ltd
Terns Pharmaceuticals Inc
Tiziana Life Sciences Plc
TRACON Pharmaceuticals Inc
Vascular Biogenics Ltd
Verlyx Pharma Inc
Viking Therapeutics Inc
Visionary Pharmaceuticals Inc
WAVE Life Sciences Ltd
Zafgen Inc
Zebra Discovery Ltd

Get in touch with us:
Ritesh Tiwari, Director
USA: +1-800-416-3124

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: *Industry Press Release is a part of Research By Markets.